Scandinavian Real Heart

Realheart Is Granted Patent Approval in India for Its Device Used in the Surgical Implantation of Realheart® TAH

Västerås, Sweden, November 20, 2024 – Scandinavian Real Heart AB (publ) announces today that the company has been granted an approval by Intellectual Property India for its patent application (no. 202117045813) concerning a technical application related to the clinical use of Realheart® TAH.

The approved patent pertains to a vascular coupling device, which is used to connect Realheart® TAH to the major vessels of the circulatory system. The duration of the patent (no. 552361) is 20 years, which will thus expire in April 2042.

“We are very happy that the patent authority in India has granted us a patent approval that complements and further strengthens our IP portfolio in India, which is a valuable as fast-growing market. While the U.S. remains our most prioritized market in the short term, we see great potential in the Indian market to realize the company’s long term growth potential,” says Ina Laura Perkins, CEO of Realheart.

Datum 2024-11-20, kl 08:30
Källa MFN
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet